Celularity Inc CELU

$1.60 +0.22 (15.94%)

Valuation

Market cap
46,314,000
Revenue TTM
$26,550,000
Net income TTM
$-91,720,000
PE ratio
0.00
Forward PE
—
Profit margin
-345.46%
Debt to equity
-1.26

Trading

Volume
221,800
Avg volume
4,959,138
Day's range
$1.36 – $1.64
Shares out
28,946,000
Stochastic %K
93%
Beta
0.77
Analysts
Strong Buy
Price target
$6.00

Price

Company profile

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therap...

Show more

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
908 768 2170
Website
https://www.celularity.com
Address
170 Park Avenue, Florham Park, United States

Latest news

Stocktwits

Dtradeyou1 Oct 2, 6:59 PM
$CELU Naveen is a money magnet!
0 replies
danielmaia12 Oct 2, 4:00 PM
This Gladiator guy below consistently gets in early on some nice runners. Made me 11k profit recently 💎💸 Highly recommend Following @GladiatorPicks , Actually a decent trader. 🔥 $CELU / $OCG on the move too
0 replies
Nosay Oct 2, 3:03 PM
$CELU maybe Q2 after hours? You know things are coiled tightly when you’re up 15% and no one has even bothered posting. Up that much on only 100k volume. Be interesting where this goes once compliant. I think even the h8ter dude would have to admit the risk of bankruptcy is gone.
1 replies
Dtradeyou1 Oct 2, 2:46 PM
$CELU Everything He touches turns to Billion dollar companies!
1 replies
Dtradeyou1 Oct 2, 2:42 PM
$CELU
0 replies
luckydog2 Oct 1, 10:28 AM
$CELU Naveen Jain Podcast https://www.reddit.com/r/CelularityNews/s/1EuhUjpjiN
0 replies
luckydog2 Sep 30, 4:00 PM
$CELU Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner Fontaine Vitale represents a significant new market and revenue opportunity for Celularity in the Asia-Pacific region https://www.globenewswire.com/news-release/2026/09/30/3372229/0/en/celularity-highlights-anticipated-quarter-one-2027-opening-of-fontaine-vitale-as-strategic-partner.html?_gl=1*gsx3i*_up*MQ..*_ga*MTU5NTU1NzAuMTc5MDc4Mzk3Nw..*_ga_B6167QB2TF*czE3OTA3ODM5NzYkbzEkZzAkdDE3OTA3ODM5NzYkajYwJGwwJGgxNTg2MTQwNTQ.*_ga_ERWPGTJ5X8*czE3OTA3ODM5NzYkbzEkZzAkdDE3OTA3ODM5NzYkajYwJGwwJGgw
0 replies
SkywalkerAR Sep 30, 4:00 PM
$CELU https://www.pressviewer.com/ViewEmail.asp?b=2739&id=410428&p=2455913&I=1477154-T9w9v6a3E9
0 replies